{"title":"脑脊液和血清中针对胰岛素-胰岛素样生长因子2 (INS-IGF2)蛋白的抗体反应性与精神分裂症或相关精神病患者的精神病症状相关。","authors":"Kristina Melkersson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Evidence has accumulated that an autoimmune-mediated process may underlie development of schizophrenia, and in two recent studies, we found increased antibody reactivity against the insulin receptor-A (INSR-A) and insulin-like growth factor 1 receptor (IGF1R) and their ligands (insulin and insulin-like growth factor 1) in cerebrospinal fluid (CSF) and/ or serum from patients with schizophrenia or related psychosis. The aim of this study was to analyze antibody reactivity in schizophrenia against the insulin-insulin-like growth factor 2 (INS-IGF2) protein, which hypothetically also may be a ligand to INSR-A and IGF1R and involved in the pathogenesis of schizophrenia.</p><p><strong>Material and methods: </strong>Patients with schizophrenia or related psychosis and controls were analyzed regarding antibody reactivity against INS-IGF2 in CSF (n = 12/ n = 11) and serum (n = 17/ n = 11), using bead-based antigen arrays of one protein fragment and 24 peptides of this protein. Additionally, the patients were assessed for clinical symptoms with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia.</p><p><strong>Results: </strong>Significantly higher antibody reactivity against the peptides 11 and 12 was found in patients in partial than full symptom remission. Patients' antibody reactivity against the peptides 5, 11 and 12 correlated positively to their PANSS scores of positive symptoms. Furthermore, significantly higher antibody reactivity against the peptides 2, 3, 10 and 22 was found in patients with, than without, heredity for diabetes mellitus type 1 or 2.</p><p><strong>Conclusion: </strong>The findings in this study pointed that the INS-IGF2 protein may be present in the CNS and involved in the autoimmune-mediated process underlying the development of schizophrenia.</p>","PeriodicalId":94154,"journal":{"name":"Neuro endocrinology letters","volume":"46 1","pages":"1-14"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antibody reactivity in cerebrospinal fluid and serum against the insulin-insulin-like growth factor 2 (INS-IGF2) protein is associated with psychotic symptomatology in patients with schizophrenia or related psychosis.\",\"authors\":\"Kristina Melkersson\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Evidence has accumulated that an autoimmune-mediated process may underlie development of schizophrenia, and in two recent studies, we found increased antibody reactivity against the insulin receptor-A (INSR-A) and insulin-like growth factor 1 receptor (IGF1R) and their ligands (insulin and insulin-like growth factor 1) in cerebrospinal fluid (CSF) and/ or serum from patients with schizophrenia or related psychosis. The aim of this study was to analyze antibody reactivity in schizophrenia against the insulin-insulin-like growth factor 2 (INS-IGF2) protein, which hypothetically also may be a ligand to INSR-A and IGF1R and involved in the pathogenesis of schizophrenia.</p><p><strong>Material and methods: </strong>Patients with schizophrenia or related psychosis and controls were analyzed regarding antibody reactivity against INS-IGF2 in CSF (n = 12/ n = 11) and serum (n = 17/ n = 11), using bead-based antigen arrays of one protein fragment and 24 peptides of this protein. Additionally, the patients were assessed for clinical symptoms with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia.</p><p><strong>Results: </strong>Significantly higher antibody reactivity against the peptides 11 and 12 was found in patients in partial than full symptom remission. Patients' antibody reactivity against the peptides 5, 11 and 12 correlated positively to their PANSS scores of positive symptoms. Furthermore, significantly higher antibody reactivity against the peptides 2, 3, 10 and 22 was found in patients with, than without, heredity for diabetes mellitus type 1 or 2.</p><p><strong>Conclusion: </strong>The findings in this study pointed that the INS-IGF2 protein may be present in the CNS and involved in the autoimmune-mediated process underlying the development of schizophrenia.</p>\",\"PeriodicalId\":94154,\"journal\":{\"name\":\"Neuro endocrinology letters\",\"volume\":\"46 1\",\"pages\":\"1-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro endocrinology letters\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro endocrinology letters","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:越来越多的证据表明,自身免疫介导的过程可能是精神分裂症发展的基础,在最近的两项研究中,我们发现精神分裂症或相关精神病患者脑脊液(CSF)和/或血清中针对胰岛素受体- a (INSR-A)和胰岛素样生长因子1受体(IGF1R)及其配体(胰岛素和胰岛素样生长因子1)的抗体反应性增加。本研究的目的是分析精神分裂症患者对胰岛素-胰岛素样生长因子2 (INS-IGF2)蛋白的抗体反应性,该蛋白也可能是INSR-A和IGF1R的配体,并参与精神分裂症的发病机制。材料和方法:采用1个蛋白片段和该蛋白的24个多肽的头部抗原阵列,分析精神分裂症或相关精神病患者和对照组脑脊液(n = 12/ n = 11)和血清(n = 17/ n = 11)中针对INS-IGF2的抗体反应性。此外,用精神分裂症阳性和阴性综合征量表(PANSS)评估患者的临床症状。结果:在症状部分缓解的患者中,抗体对肽11和肽12的反应性明显高于症状完全缓解的患者。患者对肽5、11和12的抗体反应性与其阳性症状的PANSS评分呈正相关。此外,有1型或2型糖尿病遗传的患者抗体对肽2、3、10和22的反应性明显高于无遗传的患者。结论:本研究结果提示INS-IGF2蛋白可能存在于中枢神经系统中,参与了精神分裂症发生的自身免疫介导过程。
Antibody reactivity in cerebrospinal fluid and serum against the insulin-insulin-like growth factor 2 (INS-IGF2) protein is associated with psychotic symptomatology in patients with schizophrenia or related psychosis.
Objectives: Evidence has accumulated that an autoimmune-mediated process may underlie development of schizophrenia, and in two recent studies, we found increased antibody reactivity against the insulin receptor-A (INSR-A) and insulin-like growth factor 1 receptor (IGF1R) and their ligands (insulin and insulin-like growth factor 1) in cerebrospinal fluid (CSF) and/ or serum from patients with schizophrenia or related psychosis. The aim of this study was to analyze antibody reactivity in schizophrenia against the insulin-insulin-like growth factor 2 (INS-IGF2) protein, which hypothetically also may be a ligand to INSR-A and IGF1R and involved in the pathogenesis of schizophrenia.
Material and methods: Patients with schizophrenia or related psychosis and controls were analyzed regarding antibody reactivity against INS-IGF2 in CSF (n = 12/ n = 11) and serum (n = 17/ n = 11), using bead-based antigen arrays of one protein fragment and 24 peptides of this protein. Additionally, the patients were assessed for clinical symptoms with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Results: Significantly higher antibody reactivity against the peptides 11 and 12 was found in patients in partial than full symptom remission. Patients' antibody reactivity against the peptides 5, 11 and 12 correlated positively to their PANSS scores of positive symptoms. Furthermore, significantly higher antibody reactivity against the peptides 2, 3, 10 and 22 was found in patients with, than without, heredity for diabetes mellitus type 1 or 2.
Conclusion: The findings in this study pointed that the INS-IGF2 protein may be present in the CNS and involved in the autoimmune-mediated process underlying the development of schizophrenia.